Katairo GmbH
A biopharmaceutical company focused on discovering, developing and commercializing novel treatments for back of the eye diseases.
Katairo’s lead development is remofuscin for the treatment of stargardt disease (Phase II).
Katairo has also planned to develop remofuscin for the treatment of dry age-related macular degeneration, with the next study in Phase II.
Latest Katairo GmbH News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze